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ABSTRACT
Cytosolic DNA sensors are a subgroup of pattern recognition receptors (PRRs)
and are activated by the abnormal presence of the DNA in the cytosol. Their activation
leads to the upregulation of pro-inflammatory cytokines and chemokines and can also
induce cell death. The presence of cytosolic DNA sensors and inflammatory cytokines
in TS/A murine mammary adenocarcinoma and WEHI 164 fibrosarcoma cells was
demonstrated using real time reverse transcription polymerase chain reaction (RTPCR), western blotting and enzyme-linked immunosorbent assay (ELISA). After
electrotransfer of plasmid DNA (pDNA) using two pulse protocols, the upregulation
of DNA-depended activator of interferon regulatory factor or Z-DNA binding protein
1 (DAI/ZBP1), DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 (DDX60) and interferoninducible protein 204 (p204) mRNAs was observed in both tumor cell lines, but
their expression was pulse protocol dependent. A decrease in cell survival was
also observed; it was cell type, DNA concentration and pulse protocol dependent.
Furthermore, the different protocols of electrotransfer led to different cell death
outcomes, necrosis and apoptosis, as indicated by an annexin V and 7AAD assays.
The obtained data provide new insights on the presence of cytosolic DNA sensors in
tumor cells and the activation of different types of cells death after electrotransfer
of pDNA. These observations have important implications on the planning of gene
therapy or DNA vaccination protocols.

INTRODUCTION

bleomycin and cisplatin into the cells of several tumor
types (electrochemotherapy or ECT), resulting in increased
antitumor effectiveness of chemotherapeutic drugs leading
to high percentage of complete tumor regressions [2–6].
Currently, ECT is performed in more than 140 cancer
centers in Europe and is included in the national guidelines
for treatment in UK, Germany, Slovenia and other EU
countries. Another application of electroporation that
has reached clinical trials is gene electrotransfer, where
electroporation is used for transfection of cells within
tissues with plasmid DNA (pDNA), generally for the

Electroporation (EP) is a delivery method in which
cells are exposed to electric pulses with specific intensities
and durations in order to increase the permeability of the
cell membrane, enabling transition of polar molecules
into the cells. In biomedicine, this technique is widely
used to transform bacteria and transfect eukaryotic cells
and tissues [1]. Furthermore, this technique has reached
clinical applications. In oncology, EP is used clinically
to facilitate the entry of the chemotherapeutic agents
www.oncotarget.com
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and complete regression of tumors in vivo [34, 35]. These
effects were accompanied by increased production of
interferon β (IFNβ) both in vitro and in vivo implicating
paracrine-autocrine signaling leading to cell death [25].
Tumor regression and increased cell death in vitro
have been demonstrated for other tumors such as sarcomas
and carcinomas, and for tumor cell lines, following
electrotransfer of pDNA devoid of therapeutic genes
[36–45]. However, it is not known whether other tumor
cell types of mesoderm origin (fibrosarcoma) and ectoderm
origin (carcinoma) respond to pDNA electrotransfer in a
manner similar to melanoma cells. Because the activation of
immune system is important for planning and developing new
treatment modalities for cancer, three different types of DNA
electrotransfer pulse protocols were evaluated for potential
upregulation of cytosolic DNA sensors and the downstream
consequences of their activation, such as the production of
pro-inflammatory molecules and induced cell death.

purpose of cancer therapy, cancer vaccines, or infectious
disease vaccines. In oncology, several clinical trials are
ongoing for several types of cancer using pDNA encoding
different therapeutic molecules, either immunomodulatory
molecules such as interleukin-12 [7] or tumor associated
antigens [8–11].
Although EP is used clinically, the electrical
parameters for gene electrotransfer differ substantially
depending on the therapeutic use. Tissue type, local
or systemic type of expression as well as its duration,
which are crucial for successful treatment outcomes, also
affect the choice of electrical parameters for effective
gene transfer. Currently, no universal pulse protocol
exists for specific tissue applications, although three
primary pulse protocols are used for tissue transfection.
In the first, the same electrical parameters are used as
in electrochemotherapy [12]. Plasmid delivery with this
pulse protocol has reached tumor targeted clinical trials in
the United States for melanoma [7], Merkel cell carcinoma
[13], squamous cell carcinoma, and triple-negative breast
cancer (ClinicalTrials.gov). In the second, electric pulses
of lower amplitude and longer duration are used [14, 15].
This pulse type has reached clinical trials for muscle
delivery [8]. Finally, a combination of high voltage and
low voltage electric pulses can be utilized [16, 17]. This
combination of pulse types has reached clinical trials for
intratumor delivery [18].
At the cellular level, the mechanisms of
electrotransfer-mediated pDNA entry are not fully
understood. After the exposure of the cell to electric pulses
in the presence of pDNA, a DNA-membrane complex is
formed on the membrane facing the cathode [19, 20],
then this complex enters the cells via endocytosis [21] or
macropinocytosis [22]. DNA escapes intracellular vesicles
to enter the cell’s nucleus to be transcribed then translated
into the therapeutic protein. Only DNA that enters the cells
via these mechanisms is transcribed, because inhibitors of
endocytosis almost completely abrogate the expression of
pDNA-encoded genes [23, 24].
In our previous study, we showed that the mRNAs
and proteins of the receptors of the innate immune system
that recognize foreign DNA (cytosolic DNA sensors)
were upregulated after vector pDNA (plasmid backbone
without therapeutic gene) electrotransfer in B16F10
melanoma cells [25]. This indicated that DNA is detected
in the cytosol after endosomal escape or hypothetically
it may also enter directly via electropores formed in the
cell membrane [26–28]. Cytosolic DNA sensors are a
subgroup of pattern recognition receptors (PRRs) and
are activated by the abnormal presence of the DNA in
the cytosol. Their activation leads to the upregulation
of pro-inflammatory cytokines and chemokines, which
may induce and inflammatory immune response. This
activation can also lead to cell death [29–33]. In addition
to upregulation of several cytosolic DNA sensors, in our
previous studies, we showed increased cell death in vitro
www.oncotarget.com

RESULTS
Transfection efficiency, cytotoxicity and ATP
levels
Transfection efficiency, cell survival, and ATP
levels were quantified after electrotransfer into TS/A and
WEHI 164 cells using three different pulse protocols. The
number of transfected cells, or transfection efficiency, was
pulse protocol dependent. Pulse protocol EP2 produced
a significantly higher transfection efficiency in both
cell lines than the other pulse protocols, with 39.7 ±
4.8% fluorescent cells in TS/A cell line and 74.9 ± 0.8%
in WEHI 164. Both the EP1 and EP3 pulse protocols
transfected less than 10% of cells (Figure 1).
Although the transfection efficiency varied greatly
between the pulse protocols, in TS/A cells no statistically
significant changes in median fluorescence intensity
between pulse protocols were observed. Whereas, in
WEHI 164 cells, the fluorescence intensity of cells
following transfection with the EP1 pulse protocol was
statistically significantly higher than fluorescence intensity
of cells transfected with the other two pulse protocols,
indicating that although this pulse protocol is very
cytotoxic (Figure 2), it enables higher numbers of plasmid
copies to enter the cell’s nucleus for expression.
The EP1 pulse protocol was less cytotoxic to TS/A
cells (Figure 2A) than to WEHI 164 cells (Figure 2B);
the application of EP1 pulses alone decreased the survival
fraction by 49% in TS/A cells and 67% in WEHI 164
cells. Cell survival was less affected in either cell line after
application of pulse protocols EP2 or EP3 alone (Figure
2A, 2B). For pulse protocols EP1 and EP2, the addition of
pDNA further decreased cell viability in a dose-dependent
manner that was particularly detectable in WEHI 164 cells
(Figure 2B). On the other hand, the addition of pDNA had
no effect on cell survival after the application of the EP3
18666
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pulse protocol; therefore, this protocol was not tested in
subsequent experiments.
Thirty minutes after gWiz Blank electrotransfer
with EP1 and EP2, ATP levels were measured (Figure 2C,
2D, Supplementary Table 2) to determine if the observed
difference in the cytotoxic effects between electrotransfer
pulse protocols was due to ATP leakage, which can cause
cell necrosis.
A significant decrease in ATP levels was observed after
pulse delivery. The decrease after EP1 pulse delivery alone
was significantly greater than the decrease after EP2 pulses
alone. The addition of pDNA further reduced ATP levels in
cells using EP1 but not EP2 for delivery of pDNA (p < 0.05).

of apoptosis (early apoptosis) or necrosis (accompanied
by late apoptosis) depended on the cell line and the
electrotransfer protocol. In TS/A cells, both necrotic and
apoptotic cells were detected with both EP pulse protocols
20 hours after electrotransfer of pDNA (Figure 2E); cell
death was higher after EP1 pulses (Figure 2A). In WEHI
164 cells, we observed a greater number of apoptotic cells
after pDNA electrotransfer using pulse protocol EP2 (p <
0.05), and a greater number of necrotic cells after pDNA
electrotransfer using pulse protocol EP1 (p < 0.05) (Figure
2F). These results were confirmed morphologically using
Giemsa staining perfomed 6 hours after electrotranfer of
pDNA (Supplementary Figures 1, 2). Several necrotic cells
were observed after electrotransfer of pDNA using pulse
protocol EP1 in both cell lines. Based on Giemsa staining,
we confirmed that a greater quantity of apoptotic cells were
produced after electrotransfer using the EP2 pulse protocol
in WEHI 164 cells.

Cell death mechanisms and morphology
We investigated the mechanisms of cell death using
pulse protocols EP1 and EP2. Differences in the level

Figure 1: Transfection efficiency of TS/A and WEHI 164 cell lines after pEGFP-N1 electrotransfer using three different
pulse protocols of DNA electrotransfer. pEGFP-N1 was electrotransfered by delivery of eight 5 ms pulses with a voltage to distance
ratio of 600 V/cm, frequency 1 Hz (EP1), six 100 µs pulses with a voltage to distance ratio of 1300 V/cm, frequency 4 Hz (EP2) or with
combination of one 100 µs pulse with a voltage to distance ratio 600 V/cm and four 100 ms pulses with a voltage to distance ratio 80 V/
cm, duration, frequency 1Hz (EP3) using plate electrode. *statistically significant difference of percentage of fluorescent cells between
electrotransfer protocol groups (P < 0.05). †Statistically significant difference between the mean values of median fluorescence intensity of
cells receiving the EP1 protocol and fluorescence intensity of cells receiving the EP2 and EP3 pulse protocols.
www.oncotarget.com
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Increased expression of DNA sensors depends on
pulse protocol selection and cell type

ZBP1 and p204 mRNAs occurred in both cell lines with
variation in the level of expression depending on the
cell line and the EP pulse protocol used (Tables 1, 2).
There were, however, differences between cell lines.
DEAH (Asp-Glu-Ala-His) box helicase 36 (DHX36)
was significantly upregulated in TS/A cells after pDNA
delivery with EP1. The mRNAs for leucine-rich repeat
flightless-interacting protein 1 (LRRFIP1), interferon
activated gene 202 (p202), and p204 were minimally but
significantly upregulated after pDNA delivery with EP2
in WEHI 164 cells.

The mRNAs for several PRRs were detected in
both TS/A (Table 1) and WEHI 164 cells (Table 2), while
the mRNAs for toll-like receptor 9 (TLR9), retinoic
acid inducible gene I (RIG1), and absent in melanoma 2
(AIM2) were not. SRY box 2 (SOX2) mRNA was detected
in WEHI 164 but not TS/A cells. After vector pDNA
electrotransfer, several DNA sensors were upregulated at
the mRNA level. Increased expression of DDX60, DAI/

Figure 2: Cell survival, ATP level determination and cell death mechanism after electrotransfer in TS/A and WEHI 164
cell lines. Cell survival was measured 72 hours after electrotransfer of pDNA using the pulse protocols described in methods and Figure

1 in (A) TS/A cells and (B) WEHI 164 cells. The survival fraction was normalized to an unexposed control group. The concentrations on
X-axis represent final pDNA concentrations; 10 µg/106 cells, 20 µg/106 cells and 35 µg/106 cells in 50 µl of total volume, respectively. The
percentage of ATP inside (C) TS/A and (D) WEHI 164 cells was determined immediately after electrotransfer. Cell death mechanisms were
quantified in (E) TS/A and cells (F) WEHI 164 cells for the EP1 and EP2 electrotransfer protocols in the presence and absence of pDNA
by flow cytometry for Annexin V and 7-AAD. *Statistically significant difference compared to different electrotransfer pulse protocol (EP)
groups (P < 0.05). †statistically significant difference between indicated groups (P < 0.05). #statistically significant difference from pDNA
group (p < 0.05).
www.oncotarget.com
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Table 1: Fold changes in mRNA levels of endosomal and cytosolic DNA sensors in TS/A tumor cells 4 hours after pDNA
electrotransfer
TS/A

control

gWiz Blank

EP1

EP2

EP3

pDNA+EP1

pDNA+EP2

pDNA+EP3

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

TLR9

8

/

6

/

3

/

2

/

3

/

4

/

3

/

3

/

RIG-1

8

/

6

/

3

/

2

/

3

/

4

/

3

/

3

/

DDX60

9

1.2 ± 0.3

6

0.7 ± 0.3

4

0.7 ± 0.2

2

1.7 ± 1.2

3

0.8 ± 0.0

7

3.2 ± 0.7*

5

4.0 ± 0.9*

3

1.0 ± 0.2

DHX9

8

1.2 ± 0.2

6

0.3 ± 0.1

4

0.4 ± 0.1

2

1.7 ± 1.2

3

1.3 ± 0.2

4

0.1 ± 0.0

3

1.4 ± 0.3

3

0.8 ± 0.1

DHX36

9

1.3± 0.4

6

0.6± 0.1

4

0.9 ± 0.3

2

1.7 ± 1.2

3

0.9 ± 0.1

4

7.7 ± 1.2*

5

1.9 ± 1.0

3

0.6 ± 0.1

AIM

8

/

5

/

3

/

2

/

3

/

3

/

3

/

3

/

cGAS

7

1.4 ± 0.5

5

1.1 ± 0.3

3

1.0 ± 0.4

2

1.9 ± 1.1

3

1.7 ± 0.1

3

1.6 ± 0.6

3

1.0 ± 0.1

3

1.1 ± 0.1

DAI/ZBP1

8

1.7 ± 0.5

4

1.5 ± 1.2

3

0.7 ± 0.1

2

1.7 ± 1.2

3

1.1 ± 0.2

5

14.1 ± 3.9*

3

3.0 ± 0.6*

3

1.0 ±0.1

DDX41

6

1.1 ± 0.2

4

1.3 ± 0.2

3

1.6 ± 0.4

2

1.8 ± 1.1

3

1.2 ± 0.2

3

1.3 ± 0.5

3

1.3 ± 0.2

3

0.9 ± 0.0

LRRFIP1

6

0.8 ± 0.1

5

0.8 ± 0.1

3

1.1 ± 0.2

2

1.8 ± 1.1

3

1.2 ± 0.1

3

2.2 ± 0.8

3

2.8 ± 1.2

3

0.9 ± 0.0

P202

7

1.2 ± 0.2

5

0.8 ± 0.3

3

0.7 ± 0.3

2

1.7 ± 1.2

3

0.9 ± 0.0

3

2.8 ± 1.0

3

4.1 ± 2.4

3

1.0 ± 0.1

P204

3

1.0 ± 0.2

2

1.0 ± 0.1

2

0.6 ± 0.1

2

1.9 ± 0.5

3

1.2 ± 0.1

3

1.1 ± 0.1

3

3.4 ± 0.3

3

2.1 ± 0.2*

SOX2

4

/

2

/

/

2

/

2

/

3

/

3

/

2

/

MRE1

4

1.2 ± 0.2

2

1.5 ± 0.4

2

0.8 ± 0.1

2

1.0 ± 0.1

2

0.6 ± 0.0

3

0.8 ± 0.2

3

0.9 ± 0.1

2

0.5 ± 0.0

Ku70

4

0.9 ± 0.2

2

1.0 ± 0.1

2

1.1 ± 0.0

2

0.8 ± 0.1

2

1.0 ± 0.0

3

1.0 ± 0.1

3

0.8 ± 0.1

2

1.0 ± 0.0

*

Legend: cGAS, cyclic guanosine monophosphate-adenosine monophosphate synthase; DAI/ZBP1, DNA-dependent activator of interferon regulatory factor; DDX41, DEAD (Asp-Glu-Ala-Asp) box polypeptide
41; DDX60, DEAD (Asp-Glu-Ala-Asp) box polypeptide 60; DHX9, DEAH (Asp-Glu-Ala-His)box helicase 9; DHX36, DEAH (Asp-Glu-Ala-His) box helicase 36; LRRFIP1, leucine-rich repeat flightlessinteracting protein 1; p204, interferon activated gene 204; p202, interferon activated gene 202; MRE11, meiotic recombination 11 homolog, double strand break repair nuclease; SOX2, SRY (sex determining
region Y)-box 2; Ku70, Lupus Ku autoantigen protein p70*statistically significant difference compared to control group (P < 0.05); ND, not detected.

Table 2: Fold changes in mRNA levels of endosomal and cytosolic DNA sensors in WEHI 164 tumor cells 4 hours after
pDNA electrotransfer
WEHI 164

control

gWiz Blank

EP 1

EP 2

EP 3

pDNA+EP1

pDNA+EP2

pDNA+EP3

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

n

foldex ± SE

TLR9

4

/

3

/

3

/

3

/

3

/

5

/

5

/

3

/

RIG-1

4

/

3

/

3

/

3

/

3

/

5

/

5

/

3

/

DDX60

4

1.0 ± 0.1

3

1.3 ± 0.3

3

1.4 ± 0.2

3

1.0 ± 0.3

3

0.4 ± 0.1

5

16.4 ± 5.4*

5

58.1 ± 22.4*

3

1.9 ± 0.2

DHX9

4

1.1 ± 0.3

3

1.3 ± 0.1

3

1.8 ± 0.4

3

1.6 ± 0.2

3

0.8 ± 0.1

5

2.0 ± 0.3

5

1.0 ± 0.2

3

1.0 ± 0.1

DHX36

4

1.0 ± 0.1

3

1.4 ± 0.5

3

1.9 ± 0.3

3

1.3 ± 0.1

3

0.5 ± 0.2

5

1.0 ± 0.4

5

1.1 ± 0.3

3

0.7 ± 0.1

AIM

4

/

3

/

3

/

3

/

3

/

5

/

5

/

3

/

cGAS

4

1.0 ± 0.1

3

1.1 ± 0.0

3

2.4 ± 0.3

3

1.6 ± 0.1

3

1.0 ± 0.1

5

0.7 ± 0.2

5

1.2 ± 0.4

3

1.9 ± 0.2

DAI/ZBP1

4

1.0 ± 0.2

3

1.4 ± 0.4

3

1.4 ± 0.3

3

1.3 ± 0.1

3

0.5 ± 0.0

5

3.4 ± 0.1*

5

27.2 ± 1.8*

3

3.1 ± 0.3*

DDX41

4

1.0 ± 0.1

3

1.1 ± 0.2

3

1.3 ± 0.2

3

1.1 ± 0.1

3

0.7 ± 0.1

5

1.5 ± 0.3

5

1.4 ± 0.1

3

0.9 ± 0.1

LRRFIP1

4

1.1 ± 0.2

3

1.2 ± 0.3

3

1.8 ± 0.5

3

1.8 ± 0.1

3

0.8 ± 0.1

5

1.5 ± 0.1

5

*

2.7 ± 0.1

3

1.0 ± 0.2

P202

4

1.0 ± 0.2

3

1.2 ± 0.2

3

1.5 ± 0.3

3

1.2 ± 0.2

3

0.9 ± 0.1

5

1.7 ± 0.5

5

3.7 ± 0.3*

3

0.9 ± 0.2

P204

3

1.0 ± 0.0

3

1.3 ± 0.2

3

1.0 ± 0.0

3

1.0 ± 0.1

3

1.1 ± 0.1

3

2.5 ± 0.7

3

2.6 ± 0.2*

3

1.3 ± 0.2

SOX2

3

1.0 ± 0.3

3

1.0 ± 0.3

2

1.0 ± 0.3

2

1.4 ± 0.1

2

0.4 ± 0.0

2

0.5 ± 0.1

2

0.5 ± 0.2

2

0.9 ± 0.2

MRE1

3

1.0 ± 0.2

3

0.9 ± 0.2

2

1.8 ± 0.6

2

0.9 ± 0.0

2

0.6 ± 0.0

2

1.1 ± 0.1

2

0.8 ± 0.1

2

1.0 ± 0.1

Ku70

3

1.0 ± 0.2

3

0.9 ± 0.1

2

1.9 ± 0.7

2

0.8 ± 0.1

2

0.8 ± 0.0

2

1.2 ± 0.1

2

0.7 ± 0.1

2

1.2 ± 0.0

Legend: cGAS, cyclic guanosine monophosphate-adenosine monophosphate synthase; DAI/ZBP1, DNA-dependent activator of interferon regulatory factor; DDX41, DEAD (Asp-Glu-Ala-Asp) box
polypeptide 41; DDX60, DEAD (Asp-Glu-Ala-Asp) box polypeptide 60; DHX9, DEAH (Asp-Glu-Ala-His)box helicase 9; DHX36, DEAH (Asp-Glu-Ala-His) box helicase 36; LRRFIP1, leucine-rich repeat
flightless-interacting protein 1; p204, interferon activated gene 204; p202, interferon activated gene 202; MRE11, meiotic recombination 11 homolog, double strand break repair nuclease; SOX2, SRY (sex
determining region Y)-box 2; Ku70, Lupus Ku autoantigen protein p70*statistically significant difference compared to control group (P < 0.05); ND, not detected.
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Our previous study demonstrated that increased
mRNA expression for particular PRRs can translate into
increased protein levels in B16F10 melanoma cells in vitro
[25]. Here, TS/A cells were exposed to electrical pulses
using the EP1 or EP2 pulse protocols in the presence
and in the absence of pDNA. When cleared cell lysates
were analyzed by Western blotting, a significant decrease
in DAI/ZBP-1 protein expression was observed in the
EP1+pDNA experimental group (Figure 3A). This was
quite unexpected, since mRNA levels for this protein were
the most highly upregulated in this experimental group
(Table 1).
Previous work from other groups showed that
DAI/ZBP-1 resides in the cytosol with a diffuse, but
partially granular-like pattern in HeLa and L929 cells
[46, 47]. Overexpressed proteins may form inclusion
bodies that could be eliminated from the cell lysate
during centrifugation. So, the final step of centrifugation
was excluded from the lysate preparation protocol
and, when the crude lysate was analyzed by Western
blotting, significant upregulation of DAI/ZBP1 protein
was observed in EP1+pDNA and, to the lesser extent, in
EP2+ pDNA experimental groups (Figure 3B, 3C).

TS/A cells, this upregulation of approximately 30-fold was
comparable between the two pulse protocols (Figure 5A).
However, this increase was reflected in increased protein
levels only after pDNA delivery using EP1 (Figure 4C).
IFNβ upregulation was more marked in WEHI 164 cells
(Figure 4B). In these cells, the increase in IFNβ protein
levels, approximately 150-fold, was similar between the
two pulse protocols (Figure 4D).
The mRNA of the inflammatory marker TNFα
was upregulated and increased production of protein
detected after electrotransfer of pDNA. Specifically, in
TS/A cells, the increase in mRNA and protein levels were
observed only after electrotransfer of pDNA using EP1
pulse protocol (Figure 4A, 4B). In WEHI 164 cells, the
mRNA of TNFα was upregulated after electrotransfer
of pDNA with each pulse protocols (Figure 4B);
however, production of TNFα protein was increased only
after pDNA electrotransfer using EP1 pulse protocol
(Figure 4D).

Detection of mRNA IFNβ receptor (IFNAR1)
and detection of TNFα receptor (TNFR1) by
Immunohistochemistry in TS/A and WEHI 164
cell lines

Increased expression of IFNβ and TNFα after
electrotransfer

Type I interferon receptors are ubiquitously
expressed in cells [48], which was confirmed with RT-PCR
on the mRNA level in both cell lines (data not shown).
Immunocytochemical staining of cells also confirmed that
both cell lines express TNFα receptor (Figure 5B).

In each group receiving electrotransfer of pDNA, a
marker for DNA sensor activation, IFNβ, was upregulated
on the mRNA level in both cell types. (Figure 4A, 4B) In

Figure 3: Changes in DAI/ZBP-1 expression in TS/A cells. Panel (A) shows Western blot analysis of DAI/ZBP1 expression
among different experimental groups when cell lysate was cleared by centrifugation, while panel (B) shows the analysis of crude cell lysate.
Panel (C) represents the results of 3 independent experiments (mean ± standard error of the mean, n = 3; open bars represent clear lysate,
filled ones represent crude lysate;**p < 0.01; *p < 0.05).
www.oncotarget.com

18670

Oncotarget

DISCUSSION

percentage of transfected cells of both cell lines, while
pDNA delivery with the EP1 pulse protocol significantly
increased only the median fluorescence intensity in
WEHI 164 cells. This indicated that higher number of
plasmid copies were introduced into the cells. Both
types of pulse protocols were previously used in many
studies in vitro and in vivo [44, 50–52]. In vivo, in
B16F10 mouse melanomas and P22 rat carcinomas, both
pulse protocols yielded similar GFP expression, while
in other tumor models (T24 human bladder carcinoma,
SaF mouse sarcoma), the EP1 pulse protocol resulted
in higher expression [53]. Many parameters pertinent
to the tumor type, to the tumor microenvironment, to
the pDNA and to the electrical parameters influence the
transfection efficiency [17, 54–57]. Previous studies
using a combination of short, high voltage and long,
low voltage pulses showed a similar or even greater
transfection efficiency in vivo in tissues compared to
electrotransfer with EP1 and EP2 [16, 55, 58, 59]. In
vitro, the transfection efficiency using EP3 pulse protocol
in Chinese hamster ovary cells was similar to that obtained

The results of our study demonstrate that, in general,
different gene electrotransfer pulse protocols that have
different transfection efficiencies and produce different
levels of immediate cell death can have similar effect on
the expression of cytosolic DNA sensors in tumor cell
lines. Although higher transfection efficiency was obtained
in WEHI 164 cells, similar sensors (DAI/ZBP1, DDX60
and p204) were upregulated in two cell lines TS/A and
WEHI 164 as in our previous study on B16F10 melanoma
cells [49]. The EP1 protocol produced higher levels of
IFNβ and TNFα in both cell lines than the EP2 protocol;
these levels were higher in WEHI 164 than in TS/A cells.
Finally, cell death can be induced by the electrotransfer
of pDNA, with apoptosis prevalent in WEHI 164 after
delivery with the EP2 protocol and necrosis prevalent after
delivery with the EP1 protocol, while in TS/A cells both
types of cell death occurred to the same level.
We initially determined transfection efficiency.
Delivery with the EP2 pulse protocol led to a high

Figure 4: Effect of different electrotransfer pulse protocols on fold changes in mRNA and protein levels of INFβ and
TNFα. Levels of IFNβ and TNFα mRNA (A, B) were determined 4 hours after electrotransfer of vector pDNA using the pulse protocols

described in methods and Figure 1. Intracellular levels of IFNβ and TNFα in the supernatant (C, D) were measured by ELISA 4 hours after
electrotransfer.*statistically significant difference compared to electrotransfer protocol only (EP) groups (p < 0.05).
www.oncotarget.com
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with high voltage alone [66]. In contrast, our results
showed that this combined pulse protocol was not effective
for in vitro transfection of WEHI 164 fibrosarcoma
or TS/A carcinoma cells, although modifications of
this pulse protocol may be more successful. The EP3
pulse protocol used in our study had the lowest effect
on transfection efficiency (<5%), DNA sensor mRNA
upregulation (<2-fold) and cell survival (>80%) of the
pulse types tested. This pulse protocol clearly delivers
DNA more effectively to cells in an in vivo environment
[16, 58, 60, 61]. In in vivo environments, high voltage
pulses are crucial for efficient permeabilization of the
membrane which enables transfection, while low voltage
pulses provide electrophoretic force to pull negatively
charged DNA molecules toward the cell membranes
[58, 60]. This was demonstrated for skin and muscle,
while for tumors the separation of electrophoretic and
permeabilization components did not result in improved
transfection [16, 55]. The same seems true for the selected
cell lines, since the combination pulse regimen triggered
only minimal DNA entry into the cell.
The higher transfection efficiency after delivery
with the EP2 protocol indicated more efficient DNA
uptake by an endocytosis-like mechanism [21, 22]. In
TS/A cells, this higher transfection efficiency did not
correlate with the upregulation of PRR mRNAs; both
pulse protocols upregulated DDX60 and DAI/ZBP1,
while the EP1 protocol additionally upregulated DHX36,
and the EP2 protocol additionally upregulated p204. On
the other hand, a correlation between higher transfection
efficiency of EP2 protocol and larger number of

upregulated cytosolic DNA sensors was obtained in WEHI
164 cells. Delivery with pulse protocol EP3, combining
one high voltage pulse with four low voltage pulses, only
modestly transfected cells, had no effect on cell death and
only minimally upregulated p204 in TS/A cells and DAI/
ZBP1 in WEHI 164 cells. The possible explanation for
these observations could be different entry mechanisms
for pDNA [28]. During electrotransfer, DNA enters the
cell via an endocytosis-like mechanism [21, 22] but must
escape the endosomes through the cytosol to the nucleus to
be expressed. Early endosomal escape from the endosome
to the nucleus can also occur [26]. Alternatively, DNA may
be delivered directly to the cytosol through electropores
formed in the plasma membrane [27, 28]. Thus, due to
the high transfection efficiency, higher cell survival, and
pronounced upregulation of DNA sensors, the entry of
pDNA with EP2 protocol is most probably endocytosis,
while DNA entry following EP1 is more likely to be
through electropores, although other groups demonstrated
that endocytosis occurs after the use of EP1 pulses too
[21, 22].
The pulse protocols used in our study were cytotoxic
to both cell lines, even in the absence of pDNA. The most
cytotoxic was EP1 protocol, followed by EP2 protocol,
while EP3 only minimally reduced cell survival of TS/A
cells. Nanosecond pulses can directly induce apoptosis
through activation of mitochondrial signal pathways [62].
Alternatively, the destruction of the cell membrane by
subnanosecond electric pulses can lead to necrosis [63].
Electric pulses with appropriate parameters can kill cancer
cells directly through the induction of apoptosis without

Figure 5: Immunohistochemistry of TNFR1 receptor in TS/A and WEHI 164 cell line. Cells were fixed with 4%
paraformaldehyde (A, B). Cells where receptor for TNFα (TNFR1) was present were stained in orange due to the Cy3-conjugated Donkey
Anti-Rabbit IgG.
www.oncotarget.com
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induce a cytokine response and produce cell death in
vitro. Similar cytosolic DNA sensors were upregulated in
TS/A murine mammary adenocarcinoma and WEHI 164
fibrosarcoma cells after effective electrotransfer protocols
EP1 and EP2, confirming our previous study on B16F10
melanoma [72]. These results imply that many tumor cell
types respond similarly to pDNA electrotransfer.
Although, in general, the basal levels of mRNA
of the assayed PRRs were higher in TS/A cells, the
upregulation was more pronounced in WEHI 164 cells
(data not shown). The upregulation of DAI/ZBP1, DDX60,
and p204 was detected previously in B16.F10 melanoma
cells, and this was confirmed in TS/A mammary carcinoma
cells. Basal levels of p204 mRNA were higher than those
of DAI/ZBP1 and DDX60; however, the upregulation was
more dramatic for DAI/ZBP1 and DDX60. This is similar
to the results obtained by Zhu in Leydig cells, indicating
that p204 may be the first sensor to respond to presence of
DNA and that foreign DNA in the cytosol pronouncedly
increased the expression of additional DNA sensors [74].
Interestingly, additional mRNAs were minimally yet
significantly upregulated in WEHI 164 fibrosarcoma cells.
Specifically, after delivery with the EP2 pulse protocol,
LRRFIP1 and p202 were upregulated. Similar to DDX60
and DAI/ZBP1, these proteins are also known to activate
IFNβ [75, 76]. Indeed, IFNβ mRNA and protein, markers
for DNA sensor activation, were upregulated after pDNA
electrotransfer. Following EP1 delivery, protein levels
were similar between the cell types, while only WEHI 164
cells responded to delivery with EP2. Nearly every cell
type expresses IFN receptor 1, IFNAR1 [48, 77], and as
expected, both cell types express the mRNA for IFNRA1
(data not shown). This potentiates the possible autocrineparacrine effect, producing cell death.
Furthermore, upregulation of TNFα mRNA was
observed in TS/A cells after DNA electrotransfer using
EP1 pulse protocol or in WEHI 164 cells after any DNA
electrotransfer or at low levels after exposure of cells to
electric pulses alone. In WEHI 164 cells, mRNA levels
did not consistently correlate to increased protein. TNFα
protein was detected in either cell type only after delivery
with EP1. While mRNA levels can predict protein levels, a
lack of correlation is common [78].
Upregulation of DAI/ZBP1 mRNA in TS/A cells
translated into upregulation on the protein level. The
expression of DAI/ZBP1 was significantly increased after
pDNA delivery with the EP1 protocol, and, to the lesser
extent, the EP2 protocol when crude lysate containing
all the cellular components was analyzed. Unexpectedly,
the results obtained from cleared lysate containing only
soluble proteins demonstrated a significant decrease
of DAI/ZBP1 content after pDNA delivery with EP1
pulse protocol. These results lead to the suggestion
that after pDNA delivery with the EP1 pulse protocol,
which produces the lowest cell survival rate among the
pulse protocols we applied, DAI/ZBP1 protein becomes

chemical drugs [64]. In both cell lines, application of
EP1 pulses were highly cytotoxic even in the absence
of pDNA. This electrical cell damage is probably due
to the too high electric fields that cause membrane
damage resulting in electrolyte imbalance, influx of
water, osmotic swelling of the cells and consequently
cell death by necrosis [63, 65, 66]. Molecular dynamics
simulations of electroporation in several lipid systems
demonstrated that direct interaction between electric field
and phospholipids exist [67]. Furthermore, in CHO cells,
a direct interaction between the movement of membrane
phosphatidylserine and electric field was demonstrated
[68]. Thus, we can presume that the induction of necrosis
following EP1 protocol is a physical process. Interestingly,
CHO cells retained high viability using this pulse protocol,
emphasizing the variation between cell lines [69].
Enhanced toxicity of the electric pulses in presence
of the pDNA was reported in previous studies [70, 71]. In
support of these observations, the cell death mechanism in
response to the combination of pulses and DNA was both
pulse protocol and pDNA dosage dependent (Figure 2),
which is in agreement with our previous study [72],
although there are differences in cell survival between
the cell lines. Apoptosis was the major mechanism of
cell death using the EP2 pulse protocol, while necrosis
predominated when using the EP1 pulse protocol in
WEHI 164 cells. In TS/A cells, both apoptosis and
necrosis contributed equally to cell death. The cell
morphology, which was assessed six hours after the
therapy, demonstrated mainly necrotic cells death, while
the data obtained by flow cytometry 20 h after therapy,
demonstrated that both types of cell death occurred. This
difference is due to the fact that apoptosis is a longer
process than necrosis.
Cell death can also occur due to the loss of ATP
after EP [73]. A significant reduction in intracellular ATP
immediately after EP was demonstrated. This reduction
was higher after the application of the EP1 pulse protocol
than after the EP2 protocol. This reduction might indicate
that more membrane damage was produced using long,
low voltage pulses (EP1 pulse protocol) than short, high
voltage pulses (EP2) (Figure 2). However, although the
ATP loss was significant, it did not correlate with the
reduction of cell survival, thus the obtained cell death
could not be a direct consequence of the ATP loss that
occurred within 30 minutes of electrotransfer.
The presence of foreign DNA in the cell can be
detected by DNA sensors located in the cytosol or on
the endosomal membrane. The activation of cytosolic
DNA sensors takes place when these sensors detect and
bind DNA in the cytosol [29–33]. Upon activation, these
sensors induce the production of cytokines and potentially
cell death. The upregulation of both endosomal and
cytosolic DNA sensors was explored in our study. The
results demonstrate that effective electrotransfer protocols
have similar effects on the expression of DNA sensors,
www.oncotarget.com
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so abundant that it forms insoluble inclusion bodies
as overexpressed proteins do in many cases under
unfavorable conditions. This suggestion leaves the open
question of why the amount of DAI/ZBP1 is significantly
decreased in clear extract after pDNA delivery with the
EP1 pulse protocol. One possible explanation could be
that after inclusion body formation, the expression of this
protein slows, while protein molecules still present in the
cytoplasm become less abundant due to common protein
degradation processes. Additional study is required to
investigate this possibility.

Upregulation of p204, DAI/ZBP1 and DDX60
activate signaling pathways that overlap and result in
cytokine production that can lead to both apoptosis and
necrosis [29, 79–83] (Figure 6). The cell death after
electrotransfer of pDNA using the EP1 pulse protocol
could be a consequence of the production of IFNβ and
TNFα. TNFα has shown an antitumor effect on tumor
cells or tumors in combination with other treatments
[84–88]. Cell lines that possess receptors for INFβ and/
or TNFα and receptor binding can activate necroptosis or
apoptosis [89, 90]. Necroptosis is a programmed form of

Figure 6: Possible signaling pathways activated by pDNA electrotransfer of tumor cells. After electrotransfer, pDNA (red

circles) primarily enters the cell through endocytosis (blue circles). Plasmid DNA must undergo endosomal escape to enter the cytosol.
Endosomal escape can occur early in the endocytosis process or later, before pDNA enters the nucleus [21, 26]. pDNA may possibly enter
the cytosol directly via electropores formed in cell membrane [28]. The presence of pDNA inside the cytosol of different tumor cell lines is
associated with the upregulation of cytosolic DNA sensors DDX60, DAI/ZBP1 and the p204 [44, 73, 74]. If these cytosolic DNA sensors
are activated by binding pDNA, the transcription factor interferon regulator factor 3 (IRF3) is transported from the cytosol to the nucleus
to induce transcription of IFNβ and other genes [29, 47, 82, 98]. The upregulated and secreted IFNβ protein may bind to its cell-surface
receptor(s) in an autocrine or paracrine fashion, leading to transcription of pro-inflammatory and apoptotic genes. The DNA sensors p204
and DAI/ZBP1 can activate a signaling pathway which leads to the nuclear translocation of the transcription factor NF-ĸB and consequently
to transcription of pro-inflammatory cytokines, such as TNFα, which is secreted from the cell [29, 47, 80, 81, 99]. TNFα may bind to
cell-surface receptors, which leads to the activation of two different death mechanisms (apoptosis or necroptosis) [90]. Another signaling
pathway of the cytosolic DNA sensor DAI/ZBP1 leads directly to necroptosis through MLKL activation [100]. Cytosolic DNA sensors and
their signaling pathways described here are present and upregulated in mouse TS/A adenocarcinoma cells, mouse WEHI 164 fibrosarcoma
cells, and mouse B16F10 melanoma cells [25]. Other DNA sensors, whether upregulated, not upregulated, or as yet undiscovered (labeled
with “?”) may also influence these signaling pathways.
www.oncotarget.com
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necrosis that requires the proteins RIPK3, MLKL, DAI/
ZBP1 and it is induced by death receptors, interferons,
toll-like receptors, intracellular RNA and DNA sensors
[91, 92]. Otherwise, the features of necroptosis such as
disruption of cell membrane and loss of organelles are
the same as necrosis. Therefore, these death processes
cannot be morphologically distinguished. To confirm that
TS/A and WEHI 164 cells might respond in an autocrine
or paracrine action to the production of IFNβ and TNFα
proteins, the presence of IFN receptor (IFNAR1) and
TNFα receptor (TNFR1) were confirmed in both cell
lines. In TS/A cells, cell death due to the combination of
apoptosis and necrosis was observed, in WEHI 164 cells, a
higher level of necrosis was observed after DNA delivery
with both pulse protocols. Binding of proteins IFNβ and
TNFα to their receptors could contribute to different cell
death mechanisms after DNA electrotransfer.

DNA Electrotransfer pulse protocols

MATERIALS AND METHODS

Transfection efficiency

Cells were prepared and processed as previously
described [94]. Fifty µL containing 20 µg pDNA per
1 × 106 cells was pipetted between two electrodes with
2 mm gap and three different electric pulse protocols
were applied: EP1 (8 pulses, 600 V/cm, 5 ms duration
at frequency 1 Hz), EP2 (6 pulses, 1300 V/cm, 100 µs
duration at frequency 4 Hz) and EP3 (1 pulse 600 V/cm,
100 µs duration + 4 pulses 80 V/cm, 100 ms duration,
frequency 1Hz). The cells were then incubated in AMEM
or RPMI in 6-cm Petri dishes (Corning Incorporated,
Corning, NY, USA) for determination of transfection
efficiency, Adenosine triphosphate (ATP) leakage and cell
death mechanism and in ultralow attachment 6- well or 24well plates (Corning Incorporated) for cell survival assays,
determination of morphological changes and expression of
DNA sensors and selected cytokine mRNA and protein.

Two days after electrotransfer with 10 µg
pEGFP-N1 per 1 × 106 cells, the cells were imaged by
fluorescence microscopy (Olympus IX-70, Hamburg,
Germany), then trypsinized and resuspended in 400 µl
of PBS for flow cytometry analysis (FACSCanto II flow
cytometer, BD Biosciences). A 488-nm laser (air-cooled,
20 mW solid state) and 530/30-nm band-pass filter were
used for the excitation and detection of green fluorescent
protein fluorescence, respectively. A total of 20,000
events were measured. The percentage of transfected cells
represented transfection efficiency, while the fluorescence
intensity was determined as an indirect measure of the
amount of pDNA that was introduced into the cells [95].

Cell lines
TS/A murine mammary adenocarcinoma cells [93]
were cultured in advanced minimum essential medium
(AMEM, Gibco, Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 5% fetal bovine serum
(FBS, Gibco) in 5% CO2 humidified atmosphere at 37° C.
The cell line was tested for authentication in 2017 at
IDDEx Bioresearch laboratory. WEHI 164 murine
fibrosarcoma cells (ATCC CRL-1751, American Type
Culture Collection, Manassas, VA, USA) were cultured in
Roswell Park Memorial Institute Medium (RPMI-1640,
Gibco) supplemented with 5% fetal bovine serum (FBS,
Gibco) in 5% CO2 humidified atmosphere at 37° C.

Cell survival assay
Cell survival was determined 72 hours after
electrotransfer [96] of 10 µg, 20 µg, and 35 µg gWiz
Blank per 1 × 106 cells. After electrotransfer, 1 × 103
cells were incubated in 0.1 ml AMEM in 96-well plates
(Corning Incorporated) at 37° C in a 5% CO2 humidified
incubator. The viability of the cells after pulse delivery
was determined using Presto Blue (Thermo Fisher
Scientific) per manufacturer’s instructions and normalized
to the viability of control cells that were not exposed to
electric field.

Plasmids
The vector plasmid gWiz Blank was commercially
prepared (Aldevron, Fargo, ND, USA) at concentration of 2
mg/ml in physiological saline. Additionally, concentrations
of 1 mg/ml by further dilution and 3.5 mg/ml by
concentration (Concentrator plus, Eppendorf, Hamburg,
Germany) were prepared.
Plasmid EGFP-N1 (pEGFP-N1, BD Biosciences,
San Jose, CA, USA), encoding green fluorescent protein,
was used for transfection efficiency experiments. It was
isolated after amplification in a competent Escherichia
coli (TOP10; Thermo Fisher Scientific) using Maxi-Endo
Free Plasmid Kits (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. The concentration of
isolated plasmid was measured with Epoch Microplate
Spectrophotometer (BioTek Instruments, Winooski, VT,
USA).
www.oncotarget.com

ATP determination assay
Thirty minutes after electrotransfer of gWiz Blank,
1 × 106 cells were incubated in 1 ml of appropriate media
for 1h at 37° C at 5% CO2. The cells were centrifuged
(Heraeus Fresco 21 centrifuge, Thermo Fisher Scientific)
for 10 minutes at 12000 g. The supernatant was removed,
and the cell pellets were resuspended in 1 ml of boiling
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distilled water, vortexed, immediately placed on ice,
and centrifuged for 5 minutes at 4° C and 21000 g. The
samples were transferred to the white 96-well plates and
ATP content was determined (ATP determination kit,
Molecular Probes, Thermo Fisher Scientific) according to
manufacturer’s instructions.

(LI-COR, Inc., Lincoln, NE, USA). The band intensity
was quantified using Image J software [97].

Morphological changes of tumor cells after DNA
electrotransfer
Six hours after electrotransfer of gWiz Blank,
1 × 103 cells in 80 μl of PBS were transferred to a slide
chamber and centrifuge at 123 g for 4 minutes (Cytospin
2, Thermo Shandon, Runcorn, UK). The slides were air
dried then stained with Giemsa’s Azure methylene blue
solution (Merck, Darmstadt, Germany) according to the
manufacturer’s protocol. Images of cell morphological
changes were captured with a DP72 CCD camera using
Olympus BX-51 microscope (Olympus, Tokio, Japan).
Necrotic cells were characterized as eosinophilic cells
or as cell ghosts without the presence of nucleus, while
apoptotic cells characteristics included cytoplasmic
shrinkage, nuclear condensation, nuclear fragmentation
and the formation of apoptotic bodies.

Expression of PRRs and selected cytokines
Four hours after gWiz Blank electrotransfer with
pulse protocols EP1, EP2 and EP3, total RNA was
isolated from 1 × 106 cells, cDNA was synthesized and
diluted 1:10. Relative mRNA levels were determined with
quantitative RT-PCR using IDT Oligonucleotides (IDT,
Coralville, IA, USA) (Supplementary Table 1) and Syber
Select Maste Mix (Thermofisher scientific).

ELISA
Four hours after electrotransfer with gWiz Blank,
cell cultures were washed with PBS, lysed (Mammalian
Protein Extraction Buffer, GE Healthcare, Piscataway, NJ,
USA), and total protein quantified by BCA assays (Pierce
Biotechnology, Rockford, IL, USA). IFNβ was measured
by ELISA (PBL Assay Science, Piscataway, NJ, USA) in
normalized cell culture lysates. Tumor necrosis factor α
(TNFα) was measured by ELISA (Ray Biotech, Norcross,
GA, USA) in cell culture supernatants and then normalized
to the total protein levels in the lysates to account for
differences in cell number and viability.

Determination of cell death mechanisms
Based on our previous results [49], cell death
mechanism was determined twenty hours after
electrotransfer of gWiz Blank by FITC Annexin V
Apoptosis Detection Kit with 7-AAD (7-Aminoactinomycin
D) (BioLegend, San Diego, CA, USA) according to
manufacturer’s instructions for flow cytometric analysis
(FACSCanto II, BD Biosciences). A total of 20,000
events were measured. Apoptosis was evaluated by
phosphatidylserine detection in the outer plasma membrane
leaflet using Annexin V. Necrotic cells were detected with
7-AAD, which has a high DNA-binding constant and can
pass into the nucleus and bind to DNA in necrotic cells.

Western blot analysis
TS/A cells were electrotransfected with gWiz Blank
plasmid as described above using EP1 and EP2 pulse
protocols. The cells were then seeded into low-attachment
6-well plates (Corning Incorporated, Corning, NY, USA)
and incubated for 9 hours. After incubation, the cells
were lysed using RIPA buffer in accordance with the
manufacturer’s protocol (Santa Cruz Biotechnology Inc.,
Dallas, TX, USA). For the preparation of crude lysate,
the final centrifugation step was excluded. Total protein
content was determined using a Pierce BCA Protein Assay
Kit (Fisher Scientific) then adjusted with RIPA buffer.
Twenty-five µg or 40 µg of total protein (for cleared and
crude lysate, respectively) per well was separated in a
10% polyacrylamide gel, transferred onto nitrocellulose
membrane (Bio-Rad, Hercules, CA), blocked for 1 hour in
5% milk in TBS Tween-20 buffer (Fisher Scientific) and
incubated overnight at 4° C with primary antibodies: rabbit
anti-DAI/ZBP1 or rabbit anti-β-actin as a loading control
(Fisher Scientific). After washing with TBS Tween-20
buffer, the membrane was probed with Alexa Fluor 680
goat anti-rabbit secondary antibody (Fisher Scientific) for
45 min at room temperature, washed and protein bands
were visualized with Odyssey Infrared Imaging System
www.oncotarget.com

Immunohistochemistry of TNFR1 receptor
1 × 105 cells were plated in each well of µ-Chamber
12 well glass slides (Ibidi, Munich, Germany). After
24 hours the cells were fixed with 4% paraformaldehyde.
Then, the cells were stained immunohistochemically
using primary Anti-TNF Receptor I antibody (Abcam,
Cambridge, MA, USA) and Cy3-conjugated AffiniPure
Donkey Anti-Rabbit IgG as a secondary antibody (Jackson
Immuno Research, PA, USA).

Statistical analysis
For most experiments, statistical analysis was
performed by SigmaPlot 12.0 (Systac Software Inc., San
Jose, CA, USA). Statistical evaluation was made by oneway analysis of variance (one-way ANOVA). Western blot
results were analyzed by one-way ANOVA with HolmSidak test. A p-value of less than 0.05 was considered
statistically significant. ELISA results were analyzed
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by two-way ANOVA with Tukey-Kramer multiple
comparisons test (GraphPad Software, La Jolla, CA,
USA). A p-value less than 0.05 was considered significant.
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We have shown presence of cytosolic DNA sensors
in different tumor cell lines and the upregulation of several
sensors after pDNA electrotransfer. This upregulation
correlates with the expression of IFNβ and TNFα genes
and proteins. The expression of cytosolic DNA sensors
is pulse protocol dependent, as is the mechanism of cell
death. These effects may be due to both electrical cell
damage, which occurs immediately after application
of electric pulses, and to the induction of apoptosis or
necrosis through activation of cytosolic DNA sensors.
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